

1632



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Examining Operations

Application of:	Hall, et al.	Art Unit:	1632
Serial No.:	09/904,923	Examiner:	Unassigned
Filed:	July 13, 2001		
Title:	Modified Viral Surface Proteins For Binding to Extracellular Matrix Components		
Attorney			
Docket No.:	271010-463	Customer No.:	27162

TRANSMITTAL LETTER

Commissioner of Patents and Trademarks
Washington, DC 20231

SIR:

Enclosed please find the following:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of References Cited; and
4. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit **Account No. 03-0678**.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner of Patents and Trademarks
Washington, DC 20231

Raymond J. Lillie
Raymond J. Lillie, Esq.

3/31/02
Date

Respectfully submitted,

Raymond J. Lillie
Raymond J. Lillie, Esq.
Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, New Jersey 07068
T: (973) 994-1700
F: (973) 994-1744

RECEIVED
APR 07 2003
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Hall, et al.
SERIAL NO: 09/904,923 GROUP ART UNIT: 1632
FILED: July 13, 2001 EXAMINER: Unassigned
CUSTOMER NO.: 27162
FOR: Modified Vira/Surface Proteins for Binding to Extracellular Matrix
Components
ATTY/DKT NO.: 271010-463

Commissioner for Patents
Washington, DC 20231

RECEIVED

APR 07 2003

TECH CENTER 1600/2900

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

☒ §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

☐ §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

☐ The statement as specified in 37 CFR §1.97(e) set out below;
OR

☐ The fee of \$180.00 under 37 CFR §1.17(p).

___§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).



___§1.97(e) The undersigned Attorney hereby states that:

___ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or


___ no item of information contained in this Information Disclosure Statement was cited in a first communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Commissioner for Patents Washington, DC 20231	
 Raymond J. Lillie, Esq.	 Date

#175484 v1

Respectfully submitted,



Raymond J. Lillie, Esq.

Reg. No. 37,778

CARELLA, BYRNE BAIN, GILFILLAN,

CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Tel: (973)994-1700

Fax: (973)994-1744

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT

Atty. Docket:
271010-463Serial No.:
09/904,923

Applicant: Hall, et al.

Filing Date: 7/3/01

Group: 1632

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
A1	5,328,470	7/12/94	Nabel, et al.	604	101	7/26/91
B1	5,354,674	10/11/94	Hodgson	435	172.3	10/29/92
C1	5,512,421	4/30/96	Burns, et al.	435	320.1	8/10/93
D1	5,543,328	8/6/96	McClelland, et al.	435	320.1	8/13/93
E1	5,591,624	1/7/97	Barber, et al.	435	240.2	11/23/93
F1	5,643,770	7/1/97	Mason, et al.	435	172.3	7/21/94
G1	5,681,746	10/28/97	Bodner, et al.	435	350	12/30/94
H1	5,800,811	9/1/98	Hall, et al.	424	93.7	6/6/95
I1	5,985,655	10/16/99	Anderson, et al.	435	320.1	6/7/95
J1	6,004,798	12/21/99	Anderson, et al.	435	235.1	5/14/97

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub-Class	Translation
K1	334,301	9/27/89	EPO			<input type="checkbox"/> Yes <input type="checkbox"/> No
L1	WO92/06180	4/16/92	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
M1	WO93/00103	1/7/93	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
N1	WO93/09221	5/13/93	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
O1	WO93/14188	7/22/93	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
P1	WO93/20221	10/14/93	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
Q1	WO93/25234	12/23/93	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
R1	WO94/06920	3/31/94	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
S1	WO94/0323	5/11/94	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
T1	WO94/11524	5/26/94	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
U1	WO94/12626	6/9/94	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No

RECEIVED

APR 07 2003

TECH CENTER 1600/2800

APR 03 2003
MARK OFFICE

V1	WO94/27643	12/8/94	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
W1	503,225	4/22/96	SWEDEN			<input type="checkbox"/> Yes <input type="checkbox"/> No
X1	WO96/23882	8/8/96	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
Y1	WO96/30504	10/3/96	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
Z1	WO96/31602	10/10/96	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)						
A1	Kozak, et al., <u>J. Virol.</u> , Vol. 64, No. 7, Pgs. 3500-3508 (July 1990).					
B1	Defer, et al. <u>J. Virol.</u> , Vol. 64, No. 8, Pgs. 3661-3673 (Aug. 1990).					
C1	Neda, et al., <u>J. Biol. Chem.</u> , Vol. 266, No. 22, Pgs. 14143-14146 (August 5, 1991).					
D1	Salmans, et al., <u>Human Genethery</u> , Vol. 4, Pgs. 129-141 (1993).					
E1	Barinaga, <u>Science</u> , Vol. 266, Pg. 1326 (November 25, 1994).					
F1	Kasahara, et al., <u>Science</u> , Vol. 266, Pgs. 1373-1376 (November 25, 1994).					
G1	Wong, et al., <u>Bone Marrow Trans. Exp.</u> , Abstract r001, Pg. 2640.					
H1	Valesia, et al, <u>J. Virol.</u> , Vol. 70, No. 3 Pgs. 2059-2064 (March 1996).					
I1	Xie, et al., <u>J. Biol. Chem.</u> , Vol. 271, No. 14, Pgs. 8121-8125 April 5, 1996).					
J1	Hall, et al., <u>Human Gene Therapy</u> , Vol 8, Pgs. 2183-2192 (December 10, 1997).					
Examiner:			Date Considered:			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.						

#175528 v1

RECEIVED
 APR 07 2003
 TECH CENTER 1600/2900